Retatrutide · dosing reference

What dose information exists for Retatrutide?

An investigational triple agonist (GIP, GLP-1, and glucagon receptors) in Phase 3 clinical development. There is no FDA-approved formulation, no approved prescribing label exists, and research chemicals sold online are unverified for purity or sterility.

Published human study doses

Human study

Intervention parameters reported in individual published human studies. Each study stays separate; parameters are never aggregated across studies.

Human studyJastreboff et al., New England Journal of Medicine (2023)

Population: 338 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related condition) without diabetes
Route: Subcutaneous injection
Dose as published: Once-weekly subcutaneous injection at assigned maintenance levels of 1 mg, 4 mg, 8 mg, or 12 mg; escalated in 4-week steps (e.g. 2 mg for 4 weeks → 4 mg for 4 weeks → 8 mg for 4 weeks → 12 mg)
Frequency: Once weekly
Duration: 48 weeks (primary endpoint at week 24)
Endpoint: Dose-dependent body-weight reduction: mean -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) at 48 weeks vs -2.1% placebo. Adverse events included dose-dependent nausea/diarrhea and transient increase in resting heart rate peaking at week 24.

Human studyTRIUMPH-1 Phase 3 Trial (Eli Lilly and Company / ClinicalTrials.gov NCT05929066)

Population: 2,335 adults with obesity or overweight and weight-related comorbidities (without diabetes)
Route: Subcutaneous injection
Dose as published: Once-weekly subcutaneous injection with maintenance target arms of 4 mg, 9 mg, or 12 mg, following stepwise monthly escalation from a 2 mg initial dose
Frequency: Once weekly
Duration: 80 weeks
Endpoint: Percentage change in body weight; topline disclosure reported up to 28.3% mean weight reduction at 80 weeks in the 12 mg cohort under the efficacy estimand. Full peer-reviewed manuscript under review.

Clinical / professional references

Clinical ref.

Protocols published by identifiable professional, clinic or pharmacy sources, recorded with author/clinic, date accessed and context.

Clinical referenceClinical Obesity Medicine Discussions & Educational Presentations

Discussions emphasize that unlike fixed trials that escalated participants to 12 mg, real-world clinical optimization favors finding the lowest effective dose (e.g. initiating at 0.5–1.0 mg or slower 2 mg step-ups) while closely monitoring resting heart rate and gastrointestinal tolerance.

Academic and clinical discussions (e.g. Dr. Ania Jastreboff, Dr. Tyna Moore, Dr. Quinn Stillson) — Professional commentary in obesity medicine masterclasses and clinical podcasts analyzing Phase 2/3 trial data. Not an established standard or approved treatment protocol.

Community-reported ranges

Community

What people report discussing or doing in forums, on Reddit and in videos. Included only to show demand and reported practice — never as clinical evidence.

Community reportedhigh discussion volume

Online forum participants frequently report conservative starting amounts (typically 0.5–2.0 mg once weekly) and slow titration, motivated by concerns regarding tachycardia and gastrointestinal sensitivity.

Retatrutide has no approved pharmaceutical formulation. Research chemicals marketed under the name 'retatrutide' are unapproved, unregulated, and frequently exhibit potency discrepancies and lack sterility assurance.
Therapept indexes these discussions solely to reflect public discourse, not as clinical guidance.

Community reports describe what people say they are doing. They are not equivalent to clinical evidence, and discussion volume says nothing about whether a practice is safe, effective or even real.

Why community reports are shown at all

People search for dose information before they search for anything else in this sector. Where discussion is widespread, pretending it does not exist helps nobody. Therapept reports the discussion — its rough shape, how common it is, and where it happens — while keeping it visibly separate from every other kind of source. Community reports describe what people say they are doing. They are not equivalent to clinical evidence.

Last reviewed 22 September 2026 · Compiled by Therapept Editorial · How these records are built